Johnson & Johnson subsidiary Janssen-Cilag International has been granted approval by the European Commission (EC) for the use of Trevicta (paliperidone palmitate three-monthly injection) for the maintenance treatment of schizophrenia in adult patients.

Available in the European Union (EU) as the longest dosing interval for an antipsychotic medication, Trevicta enables adult schizophrenia patients to maintain an optimal level of treatment in their blood with fewer administrations of the drug, compared to existing antipsychotic treatments.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Trevicta can be used for the maintenance treatment of schizophrenia in adult patients who are clinically stable on Xeplion.

Xeplion is a one-monthly paliperidone palmitate product that was approved in 2011 for the maintenance treatment of schizophrenia in the EU.

"This new option has the potential to reduce the likelihood of relapse and progression of the disease."

Janssen-Cilag Neuroscience and Pain European therapeutic area leader Dr Andreas Schreiner said: "This approval is a big step forward for people living with schizophrenia.

See Also:

"With fewer administrations per year compared to other approved treatments, trevicta can give people with schizophrenia greater freedom to focus on other important aspects of their life and less on their treatment.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"This new option has the potential to reduce the likelihood of relapse and progression of the disease. It also helps healthcare professionals ensure the person with schizophrenia can benefit from continuous delivery of medication between administrations."

The marketing authorisation for Trevicta has been granted based on two Phase III studies, the first being a randomised, multi-centre, double-blind, placebo-controlled, relapse prevention study in schizophrenia patients.

The second randomised, multi-centre, double-blind study compared the efficacy and safety of paliperidone palmitate three-monthly and one-monthly formulations.

The medication comes with a few commonly observed drug reactions such as anxiety, headache, insomnia, increased weight, upper respiratory tract infection and injection site reaction.

With the approval, Janssen-Cilag will be able to market Trevicta across all 28 EU states, as well as the European Economic Area countries including Iceland, Norway and Liechtenstein.